NAL1218

NAL1218 is a transdermal patch formulation of diclofenac epolamine, a nonsteroidal anti-inflammatory drug (NSAID), being developed by NAL Pharmaceutical Group for pain management. The product is designed as a 12-hour sustained-release patch that utilizes NAL's proprietary transdermal delivery technology. Its mechanism of action involves the non-selective inhibition of cyclooxygenase-1 (COX-1) and cyclooxygenase-2 (COX-2) enzymes, which are responsible for the synthesis of prostaglandins that mediate inflammation and pain. By delivering the active ingredient through the skin, NAL1218 aims to provide localized analgesic effects while potentially reducing the systemic side effects associated with oral NSAID administration.

Other names

Diclofenac Epolamine 12-Hour Patchdiclofenac epolamine